Objectives: To critically analyse radiotherapy cost studies published over the last 35 years. MethOds: We conducted a comprehensive and systematic review of the literature searching for radiotherapy cost calculation studies on PubMed (Medline) and Embase databases and in the grey literature. The searches yielded 1327 unique entries that were evaluated against the following selection criteria: actual medical cost, external beam radiotherapy (EBRT), clear description of the cost calculation method. The review for compliance with the criteria was conducted in three phases: title; abstract and then full manuscript. Results: Since 1981, 50 studies satisfied our selection criteria. Any perspective, e.g. societal, institutional, was considered acceptable as long as the institutional resources 'cost of radiotherapy was presented. Cost assessments of EBRT were conducted within a full economic evaluation framework (5 studies: 2 CEA, 2 CUA, and 1 CBA), cost analysis (24), cost description (18) and investment analysis (3). The scope of the selected studies ranged from comprehensive medical cost of radiotherapy including the department's overhead (20), to average cost specific to one pathology and/or treatment modality (25) to task-specific costs (7) e.g. shielding. Costs were computed per fraction and/or field (20), per treatment and/or patient (27) and specific to a treatment's process step (3). Costing methodologies ranged from detailed micro costing (13) to activity-based costing (5) to time-driven activity-based costing (2). Besides these established accounting methods, numerous "home-made" approaches were observed (23) and some studies didn't state their method (7). cOnclusiOns: Due to heterogeneity both in methodology, input factors and paucity in costing method's reporting, it was not possible to compare the cost estimates provided by these various studies. This comprehensive literature review of radiotherapy cost studies highlights the need for such studies to be conducted according to conventional accounting approaches and with rigor in the reporting of cost inputs and methodology. Objectives: The extended-release oxycodone hydrochloride is an opioid with similar action to morphine with proven efficacy in moderate to severe pain management. This study aims to develop a cost analysis of extended-release oxycodone versus morphine in an "if necessary" regime for cancer-related pain management, from the Brazilian public and private healthcare systems perspectives. MethOds: A decision model was developed to analyze the following strategies: group 1, 20 mg of extended-release oxycodone; group 2, 10 mg of extended-release oxycodone; and group 3, placebo. Efficacy data were obtained from Zhou e Wang, 2012. Direct costs were obtained from official price lists. Time horizon was determined through the hospital discharge period, and discount rates were not applied. Univariate sensitivity analysis was performed to evaluate different hospital categories. Results: Total costs were 1,103 BRL, 1,071 BRL and 1,214 BRL per patient treated, from the public perspective, in groups 1, 2 and 3, respectively. The addition of oxycodone (10 and 20 mg) to the treatment reduced hospitalization stay, leading to savings of up to 143 BRL per patient, or a 12% reduction in total hospitalization cost. Total costs were 2,372 BRL, 2,367 BRL and 2,759 BRL per patient treated, from the private perspective, in groups 1, 2 and 3, respectively. The addition of oxycodone to treatment can lead to savings of up to 392.66 BRL per patient, a reduction about 14% of the total treatment cost during hospitalization. The univariate sensitivity analysis showed consistent results. cOnclusiOns: The inclusion of extended-release oxycodone can lead to a reduction in total costs related to pain treatment in patients with cancer, which would lead to resource savings for the payer. Feuerbach M, Freigang F, Lipp R GermanOncology GmbH, Hamburg, Germany Objectives: Only a few international studies give valid information about cost of Best Supportive Care (BSC) of patients with unresectable advanced or metastatic non-small-cell lung cancer (NSCLC). The aim of this non interventional study was to compare the results of these studies with data collected under real-world-conditions in 26 oncological practices in Germany. MethOds: Data collected from oncological practices in Germany contain information about the entire course of treatment including the medication of primary disease, radiotherapy, number of outpatient specialist visits, length of hospitalisation, type and number of diagnostic and laboratory procedures. In addition, four different studies from USA, Scotland, Great Britain and the Netherlands with information about cost of BSC were examined. To compare these studies with data from the oncological practices, the results were transferred into the german reimbursement systems for health care services. The calculation for annual cost of treatment is based on methods of the Institute for Quality and Efficiency in Healthcare (IQWiG) in Germany. Results: 509 patients with NSCLC from 26 oncological practices throughout Germany were included in the statistical and cost´s analysis. Patients cal trial population were included in the estimation of total cost. HCRU costs were estimated using the mean reimbursed amounts from a cohort of breast cancer patients from the Truven Health Marketscan database. Study drug costs were estimated using the unit wholesale acquisition cost for T-DM1 and L+C. Monthly costs were calculated by dividing the total cost by the observed survival time (in months). Total costs were evaluated using the Kaplan Meier Sample Average (KMSA) estimator to account for differences in the length of follow-up and censoring between trial arms. Results: In the EMILIA clinical trial, median overall survival was 30.9 months with T-DM1 (n= 495) versus 25.1 months with L+C (n= 496) after a median of 19 months follow-up. No differences were observed in the monthly cost per-patient between T-DM1 ($7,151, 95% confidence interval [CI]: $6,753 -$7,550) and L+C ($7,909, 95% CI: $5,095 -$10,723). The KMSA mean total costs were $331,083 (95% CI: $152,238 -$506,128) and $264,421 (95% CI: $133,143-$412,927) in the T-DM1 and L+C arms, respectively. Hospitalization costs were lower among the T-DM1 arm ($9,634, 95% CI: $6,394 -$12,873) than the L+C arm ($11,286, 95% CI: $6,216 -$16,357). cOnclusiOns: Although the mean total costs were higher for T-DMI because of longer survival relative to L+C, the average monthly costs of treating patients with T-DM1 were similar to L+C. This study, along with the 5.8-month survival benefit, supports the potential value of T-DM1 for the treatment of HER2+ metastatic or locally advanced breast cancer. Objectives: To evaluate and compare surgical parameters and costs associated with robotic and laparoscopic surgery for colorectal cancer over 5-years (2009-2014) in a single Italian centre. MethOds: From 2009 to 2014 data about laparoscopic (LAP) and robotic (ROB) assisted colorectal cancer procedures performed in General Surgery, University Hospital of Pisa were collected. Operating time and length of stay were evaluated as surgical parameters and costs included fixed and variable items. Amortised cost of the robot and laparoscopic instrument and amortised cost of robot maintenance per intervention were considered among fixed costs. Variable costs included costs of dispensable equipment, cost of operating room personnel per time and costs of length-of-stay. Over the 5-years period surgical parameters and costs associated with LAP and ROB were analysed using descriptive statistics and compared between groups by independent T-test and Mann-Whitney test. Generalized linear models were used to assess the independent effect of type of surgery and time. Results: A total of 25 laparoscopic (LAP) and 50 robotic (ROB) procedures were evaluated. Overall median operating time was significantly higher in LAP (270 min vs 312.5 min, P= 0.006) and regression analysis showed a borderline significant interaction effect between type of surgery and years (P= 0.058) suggesting a significant reduction of operating time in ROB but not in LAP. Hospital-stay did not differ between groups (P= 0.567). Overall mean costs associated to LAP varied between 8,612±2,733 Euros in 2009 to 10,827±5,038 Euros in 2013. For ROB mean costs were 12,966±1,115 Euros in 2010 to 11,933±1,753 Euros in 2014. Regression analysis outlined significant greater costs for ROB (P-value< 0.001) without differences over time. cOnclusiOns: Robotic surgery for colorectal cancer carries out significant greater costs and operating time compared to laparoscopic surgery. There is weak evidence of improvement in the exploitation of ROB procedures without significant consequences on costs at present. (SD= $209,717; IQR= $94,992) for HCT recipients without dsDNA infections versus $470,784 (SD= $467,557; IQR= $193,019; p= 0.0001) for those with any dsDNA viral infection. Among allogeneic HCT recipients, reimbursements were higher. Mean (SD; IQR) costs post-transplant for allogeneic HCT recipients without infection were $320,320 (SD= $278,388; IQR= $ 53,450) versus $551,664 (SD= $503,913; IQR= $261,483; p< 0.0001) for patients with any dsDNA viral infection and $999,010 (SD= $822,223; IQR= $449,033-$1,410,000) for patients with adenovirus infection. Adenovirus infection represented 4.5% of all dsDNA viral infections. cOnclusiOns: Patients who experience dsDNA viral infection following HCT have a higher burden of reimbursement compared to those without such infections. dsDNA virus infections are most common and more costly in allogeneic HCT recipients. Measures to prevent dsDNA viral infection following HCT could result in cost savings and improved patient outcomes.
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